BRAF and hairy cell leukemia: The combination of a BRAF inhibitor with a MEK inhibitor, e.g., trematinib, for the treatment of HCL-V and HCL patients with mutations in the VH4-34 gene may be an appropriate strategy for the future (41, 46).